Bio-Techne Corp [NASDAQ: TECH] slipped around -4.77 points on Wednesday, while shares priced at $49.87 at the close of the session, down -8.73%.
Compared to the average trading volume of 2.38M shares, TECH reached a trading volume of 6682086 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bio-Techne Corp [TECH]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TECH shares is $66.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TECH stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Bio-Techne Corp shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 22, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on July 09, 2025, representing the official price target for Bio-Techne Corp stock. Previously, the target price had yet another raise to $59, while Wells Fargo analysts kept a Overweight rating on TECH stock.
The Price to Book ratio for the last quarter was 3.87, with the Price to Cash per share for the same quarter was set at 1.03. Price to Free Cash Flow for TECH in the course of the last twelve months was 35.42 with Quick ratio for the last quarter at 2.38.
How has TECH stock performed recently?
Bio-Techne Corp [TECH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.59. With this latest performance, TECH shares dropped by -5.33% in over the last four-week period, additionally sinking by -31.26% over the last 6 months – not to mention a drop of -30.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TECH stock in for the last two-week period is set at 38.06, with the RSI for the last a single of trading hit 2.57, and the three-weeks RSI is set at 2.30 for Bio-Techne Corp [TECH]. The present Moving Average for the last 50 days of trading for this stock 52.10, while it was recorded at 53.80 for the last single week of trading, and 61.97 for the last 200 days.
Bio-Techne Corp [TECH]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bio-Techne Corp [TECH] shares currently have an operating margin of 13.77% and a Gross Margin at 65.43%. Bio-Techne Corp’s Net Margin is presently recorded at 10.79%.
Bio-Techne Corp (TECH) Capital Structure & Debt Analysis
According to recent financial data for Bio-Techne Corp. ( TECH), the Return on Equity (ROE) stands at 3.68%, suggesting modest shareholder returns. The Return on Assets (ROA) is 2.73%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Bio-Techne Corp’s Return on Invested Capital (ROIC) is 5.60%, showcasing its effectiveness in deploying capital for earnings.
Bio-Techne Corp (TECH) Efficiency & Liquidity Metrics
Based on Bio-Techne Corp’s (TECH) latest financial statements, the Debt-to-Equity Ratio is 0.23%, indicating its reliance on debt financing relative to shareholder equity.
Bio-Techne Corp (TECH) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Bio-Techne Corp. (TECH) effectively leverages its workforce, generating an average of $42467.74 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.46% and a Quick Ratio of 2.38%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Bio-Techne Corp [TECH]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TECH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bio-Techne Corp go to 13.21%.
Insider trade positions for Bio-Techne Corp [TECH]
There are presently around $105.33%, or 106.48%% of TECH stock, in the hands of institutional investors. The top three institutional holders of TECH stocks are: VANGUARD GROUP INC with ownership of 18.18 million shares, which is approximately 11.5171%. BLACKROCK INC., holding 14.99 million shares of the stock with an approximate value of $$1.07 billion in TECH stocks shares; and BLACKROCK INC., currently with $$610.87 million in TECH stock with ownership which is approximately 5.4006%.
